Determine DNA variants and their allele frequencies in genes commonly mutated in myeloid malignancies and related disorders, at diagnosis, relapse and during remission. This assay serves as a primary approach and a complement to morphology, immunophenotyping by flow cytometry and cytogenetic workups.
Performing Lab
Genomic Services - Molecular Diagnostics
Performed
Run 1x per week, or as needed, day shift only
Methodology
DNA extraction and Next Generation DNA sequencing (NGS) on the Illumina platform
Reported
6-14 days
Additional Information
This Myeloid Multi Gene Panel (MMGP) Next Generation Sequencing test detects and determines the variant allele frequency (VAF) of DNA variants in exons and flanking splice sites in 52 genes (listed below) that are commonly mutated in myeloid malignancies. Pathogenicity of the detected DNA variants are reported based on established criteria in databases such as ClinVar and COSMIC, while Variants of Unknown Significance (VUS) are reported based on their potential disruption of gene and/or protein function and whether they are unlisted or occur at very low allelic frequencies in general population databases such as GnomAD.
This assay is particularly relevant for the detection of DNA variants at diagnosis of suspected myeloid malignancies and for minimal residual disease (MRD) monitoring at relapse and during remission. The sensitivity of mutation detection of this assay routinely down to 1% variant allele frequency (VAF) includes FLT3-ITD and other variants, which can also be reported at < 1% when monitoring for previously detected variants in the same patient.
To determine the FLT3 ITD allele ratio, an automatic reflex FLT3 assay by capillary electrophoresis (CE) will be ordered (with an additional charge) if a FLT3 ITD is detected and the FLT3 CE assay was not previously ordered on the same specimen. To skip this reflex test, please call the lab directly at (415)514-8488 or email ClinLabMDx@ucsf.edu.
Synonyms
MYEBL
MYENB
Acute myeloid leukemia (AML)
Chronic myeloid leukemia (CML)
Myeloproliferative disorders (MPD)
Myelodysplastic syndromes (MDS)
Next Generation Sequencing (NGS)
Sample Type
Tumor sample: EDTA whole blood, Bone marrow aspirate and FFPE tissue
Germline sample: Buccal swabs
Collect
Lavender top (EDTA)
Preferred Volume
Tumor Sample
Blood: 3 mL
Bone marrow aspirate: 3 mL
FFPE: 10 micron sections x5 on uncharged, unstained, glass slides
Germline Sample
Collect 4-6 cytobrushes/cotton swabs on each side of the mouth, place swabs in transport tubes, 2 swabs per tube.
Minimum Volume
Tumor Sample
Blood: 2 mL
Bone marrow aspirate: 2 mL
FFPE: 10 micron sections x3 on uncharged, unstained, glass slides
Germline Sample
Collect 2-4 cytobrushes/cotton swabs on each side of the mouth, place swabs in transport tubes, 2 swabs per tube.
Remarks
Do not collect sample in heparin. Keep sample refrigerated for overnight or longer storage.
Stability (from collection to initiation)
Refrigerated 1 week, frozen at -20C unacceptable.
Storage/Transport Temperature
Refrigerated
Unacceptable Conditions
Heparinized sample submitted.
Test Code
MYEBL: Blood
MYENB: Non-blood
Performing Lab
Genomic Services - Molecular Diagnostics
Preferred Volume
Tumor Sample
Blood: 3 mL
Bone marrow aspirate: 3 mL
FFPE: 10 micron sections x5 on uncharged, unstained, glass slides
Germline Sample
Collect 4-6 cytobrushes/cotton swabs on each side of the mouth, place swabs in transport tubes, 2 swabs per tube.
Minimum Volume
Tumor Sample
Blood: 2 mL
Bone marrow aspirate: 2 mL
FFPE: 10 micron sections x3 on uncharged, unstained, glass slides
Germline Sample
Collect 2-4 cytobrushes/cotton swabs on each side of the mouth, place swabs in transport tubes, 2 swabs per tube.
Unacceptable Conditions
Heparinized sample submitted.
Stability (from collection to initiation)
Refrigerated 1 week, frozen at -20C unacceptable.
Storage/Transport Temperature
Refrigerated
Reference Interval
Negative
Additional Information
This Myeloid Multi Gene Panel (MMGP) Next Generation Sequencing test detects and determines the variant allele frequency (VAF) of DNA variants in exons and flanking splice sites in 52 genes (listed below) that are commonly mutated in myeloid malignancies. Pathogenicity of the detected DNA variants are reported based on established criteria in databases such as ClinVar and COSMIC, while Variants of Unknown Significance (VUS) are reported based on their potential disruption of gene and/or protein function and whether they are unlisted or occur at very low allelic frequencies in general population databases such as GnomAD.
This assay is particularly relevant for the detection of DNA variants at diagnosis of suspected myeloid malignancies and for minimal residual disease (MRD) monitoring at relapse and during remission. The sensitivity of mutation detection of this assay routinely down to 1% variant allele frequency (VAF) includes FLT3-ITD and other variants, which can also be reported at < 1% when monitoring for previously detected variants in the same patient.
Determine DNA variants and their allele frequencies in genes commonly mutated in myeloid malignancies and related disorders, at diagnosis, relapse and during remission. This assay serves as a primary approach and a complement to morphology, immunophenotyping by flow cytometry and cytogenetic workups.
Test Code
MYEBL: Blood
MYENB: Non-blood
Performing Lab
Genomic Services - Molecular Diagnostics
Performed
Run 1x per week, or as needed, day shift only
Methodology
DNA extraction and Next Generation DNA sequencing (NGS) on the Illumina platform
Remarks
Do not collect sample in heparin. Keep sample refrigerated for overnight or longer storage.
Collect
Lavender top (EDTA)
Sample Type
Tumor sample: EDTA whole blood, Bone marrow aspirate and FFPE tissue
Germline sample: Buccal swabs
Preferred Volume
Tumor Sample
Blood: 3 mL
Bone marrow aspirate: 3 mL
FFPE: 10 micron sections x5 on uncharged, unstained, glass slides
Germline Sample
Collect 4-6 cytobrushes/cotton swabs on each side of the mouth, place swabs in transport tubes, 2 swabs per tube.
Minimum Volume
Tumor Sample
Blood: 2 mL
Bone marrow aspirate: 2 mL
FFPE: 10 micron sections x3 on uncharged, unstained, glass slides
Germline Sample
Collect 2-4 cytobrushes/cotton swabs on each side of the mouth, place swabs in transport tubes, 2 swabs per tube.
Unacceptable Conditions
Heparinized sample submitted.
Reference Interval
Negative
Synonyms
MYEBL
MYENB
Acute myeloid leukemia (AML)
Chronic myeloid leukemia (CML)
Myeloproliferative disorders (MPD)
Myelodysplastic syndromes (MDS)
Next Generation Sequencing (NGS)
Storage/Transport Temperature
Refrigerated
Stability (from collection to initiation)
Refrigerated 1 week, frozen at -20C unacceptable.
Reported
6-14 days
Reflex Testing
To determine the FLT3 ITD allele ratio, an automatic reflex FLT3 assay by capillary electrophoresis (CE) will be ordered (with an additional charge) if a FLT3 ITD is detected and the FLT3 CE assay was not previously ordered on the same specimen. To skip this reflex test, please call the lab directly at (415)514-8488 or email ClinLabMDx@ucsf.edu.
Additional Information
This Myeloid Multi Gene Panel (MMGP) Next Generation Sequencing test detects and determines the variant allele frequency (VAF) of DNA variants in exons and flanking splice sites in 52 genes (listed below) that are commonly mutated in myeloid malignancies. Pathogenicity of the detected DNA variants are reported based on established criteria in databases such as ClinVar and COSMIC, while Variants of Unknown Significance (VUS) are reported based on their potential disruption of gene and/or protein function and whether they are unlisted or occur at very low allelic frequencies in general population databases such as GnomAD.
This assay is particularly relevant for the detection of DNA variants at diagnosis of suspected myeloid malignancies and for minimal residual disease (MRD) monitoring at relapse and during remission. The sensitivity of mutation detection of this assay routinely down to 1% variant allele frequency (VAF) includes FLT3-ITD and other variants, which can also be reported at < 1% when monitoring for previously detected variants in the same patient.
Determine DNA variants and their allele frequencies in genes commonly mutated in myeloid malignancies and related disorders, at diagnosis, relapse and during remission. This assay serves as a primary approach and a complement to morphology, immunophenotyping by flow cytometry and cytogenetic workups.
Performing Lab
Genomic Services - Molecular Diagnostics
Performed
Run 1x per week, or as needed, day shift only
Methodology
DNA extraction and Next Generation DNA sequencing (NGS) on the Illumina platform
Reported
6-14 days
Additional Information
This Myeloid Multi Gene Panel (MMGP) Next Generation Sequencing test detects and determines the variant allele frequency (VAF) of DNA variants in exons and flanking splice sites in 52 genes (listed below) that are commonly mutated in myeloid malignancies. Pathogenicity of the detected DNA variants are reported based on established criteria in databases such as ClinVar and COSMIC, while Variants of Unknown Significance (VUS) are reported based on their potential disruption of gene and/or protein function and whether they are unlisted or occur at very low allelic frequencies in general population databases such as GnomAD.
This assay is particularly relevant for the detection of DNA variants at diagnosis of suspected myeloid malignancies and for minimal residual disease (MRD) monitoring at relapse and during remission. The sensitivity of mutation detection of this assay routinely down to 1% variant allele frequency (VAF) includes FLT3-ITD and other variants, which can also be reported at < 1% when monitoring for previously detected variants in the same patient.
To determine the FLT3 ITD allele ratio, an automatic reflex FLT3 assay by capillary electrophoresis (CE) will be ordered (with an additional charge) if a FLT3 ITD is detected and the FLT3 CE assay was not previously ordered on the same specimen. To skip this reflex test, please call the lab directly at (415)514-8488 or email ClinLabMDx@ucsf.edu.
Synonyms
MYEBL
MYENB
Acute myeloid leukemia (AML)
Chronic myeloid leukemia (CML)
Myeloproliferative disorders (MPD)
Myelodysplastic syndromes (MDS)
Next Generation Sequencing (NGS)
Collection
Sample Type
Tumor sample: EDTA whole blood, Bone marrow aspirate and FFPE tissue
Germline sample: Buccal swabs
Collect
Lavender top (EDTA)
Preferred Volume
Tumor Sample
Blood: 3 mL
Bone marrow aspirate: 3 mL
FFPE: 10 micron sections x5 on uncharged, unstained, glass slides
Germline Sample
Collect 4-6 cytobrushes/cotton swabs on each side of the mouth, place swabs in transport tubes, 2 swabs per tube.
Minimum Volume
Tumor Sample
Blood: 2 mL
Bone marrow aspirate: 2 mL
FFPE: 10 micron sections x3 on uncharged, unstained, glass slides
Germline Sample
Collect 2-4 cytobrushes/cotton swabs on each side of the mouth, place swabs in transport tubes, 2 swabs per tube.
Remarks
Do not collect sample in heparin. Keep sample refrigerated for overnight or longer storage.
Stability (from collection to initiation)
Refrigerated 1 week, frozen at -20C unacceptable.
Storage/Transport Temperature
Refrigerated
Unacceptable Conditions
Heparinized sample submitted.
Processing
Test Code
MYEBL: Blood
MYENB: Non-blood
Performing Lab
Genomic Services - Molecular Diagnostics
Preferred Volume
Tumor Sample
Blood: 3 mL
Bone marrow aspirate: 3 mL
FFPE: 10 micron sections x5 on uncharged, unstained, glass slides
Germline Sample
Collect 4-6 cytobrushes/cotton swabs on each side of the mouth, place swabs in transport tubes, 2 swabs per tube.
Minimum Volume
Tumor Sample
Blood: 2 mL
Bone marrow aspirate: 2 mL
FFPE: 10 micron sections x3 on uncharged, unstained, glass slides
Germline Sample
Collect 2-4 cytobrushes/cotton swabs on each side of the mouth, place swabs in transport tubes, 2 swabs per tube.
Unacceptable Conditions
Heparinized sample submitted.
Stability (from collection to initiation)
Refrigerated 1 week, frozen at -20C unacceptable.
Storage/Transport Temperature
Refrigerated
Result Interpretation
Reference Interval
Negative
Additional Information
This Myeloid Multi Gene Panel (MMGP) Next Generation Sequencing test detects and determines the variant allele frequency (VAF) of DNA variants in exons and flanking splice sites in 52 genes (listed below) that are commonly mutated in myeloid malignancies. Pathogenicity of the detected DNA variants are reported based on established criteria in databases such as ClinVar and COSMIC, while Variants of Unknown Significance (VUS) are reported based on their potential disruption of gene and/or protein function and whether they are unlisted or occur at very low allelic frequencies in general population databases such as GnomAD.
This assay is particularly relevant for the detection of DNA variants at diagnosis of suspected myeloid malignancies and for minimal residual disease (MRD) monitoring at relapse and during remission. The sensitivity of mutation detection of this assay routinely down to 1% variant allele frequency (VAF) includes FLT3-ITD and other variants, which can also be reported at < 1% when monitoring for previously detected variants in the same patient.
Determine DNA variants and their allele frequencies in genes commonly mutated in myeloid malignancies and related disorders, at diagnosis, relapse and during remission. This assay serves as a primary approach and a complement to morphology, immunophenotyping by flow cytometry and cytogenetic workups.
Test Code
MYEBL: Blood
MYENB: Non-blood
Performing Lab
Genomic Services - Molecular Diagnostics
Performed
Run 1x per week, or as needed, day shift only
Methodology
DNA extraction and Next Generation DNA sequencing (NGS) on the Illumina platform
Remarks
Do not collect sample in heparin. Keep sample refrigerated for overnight or longer storage.
Collect
Lavender top (EDTA)
Sample Type
Tumor sample: EDTA whole blood, Bone marrow aspirate and FFPE tissue
Germline sample: Buccal swabs
Preferred Volume
Tumor Sample
Blood: 3 mL
Bone marrow aspirate: 3 mL
FFPE: 10 micron sections x5 on uncharged, unstained, glass slides
Germline Sample
Collect 4-6 cytobrushes/cotton swabs on each side of the mouth, place swabs in transport tubes, 2 swabs per tube.
Minimum Volume
Tumor Sample
Blood: 2 mL
Bone marrow aspirate: 2 mL
FFPE: 10 micron sections x3 on uncharged, unstained, glass slides
Germline Sample
Collect 2-4 cytobrushes/cotton swabs on each side of the mouth, place swabs in transport tubes, 2 swabs per tube.
Unacceptable Conditions
Heparinized sample submitted.
Reference Interval
Negative
Synonyms
MYEBL
MYENB
Acute myeloid leukemia (AML)
Chronic myeloid leukemia (CML)
Myeloproliferative disorders (MPD)
Myelodysplastic syndromes (MDS)
Next Generation Sequencing (NGS)
Storage/Transport Temperature
Refrigerated
Stability (from collection to initiation)
Refrigerated 1 week, frozen at -20C unacceptable.
Reported
6-14 days
Reflex Testing
To determine the FLT3 ITD allele ratio, an automatic reflex FLT3 assay by capillary electrophoresis (CE) will be ordered (with an additional charge) if a FLT3 ITD is detected and the FLT3 CE assay was not previously ordered on the same specimen. To skip this reflex test, please call the lab directly at (415)514-8488 or email ClinLabMDx@ucsf.edu.
Additional Information
This Myeloid Multi Gene Panel (MMGP) Next Generation Sequencing test detects and determines the variant allele frequency (VAF) of DNA variants in exons and flanking splice sites in 52 genes (listed below) that are commonly mutated in myeloid malignancies. Pathogenicity of the detected DNA variants are reported based on established criteria in databases such as ClinVar and COSMIC, while Variants of Unknown Significance (VUS) are reported based on their potential disruption of gene and/or protein function and whether they are unlisted or occur at very low allelic frequencies in general population databases such as GnomAD.
This assay is particularly relevant for the detection of DNA variants at diagnosis of suspected myeloid malignancies and for minimal residual disease (MRD) monitoring at relapse and during remission. The sensitivity of mutation detection of this assay routinely down to 1% variant allele frequency (VAF) includes FLT3-ITD and other variants, which can also be reported at < 1% when monitoring for previously detected variants in the same patient.
